Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | ENERGIZE: chemo + nivo with/without linrod for bladder cancer

Guru Sonpavde • 15 Feb 2020
GU Cancers 2020
Bladder Cancer Genitourinary Cancer Antibodies Checkpoint Inhibitors Cisplatin Gemcitabine Linrodostat Nivolumab
ENERGIZE

Guru Sonpavde, MD, Dana-Farber Cancer Institute, Boston, MA, outlines ENERGIZE (NCT03661320), a Phase III trial investigating the efficacy of neoadjuvant chemotherapy in combination with nivolumab (nivo) with or without linrodostat (linrod) followed by postsurgery nivolumab or nivolumab with linrodostat in cisplatin-eligible patients with muscle-invasive bladder cancer. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Guru Sonpavde

How will EIK1003 fit in the treatment landscape of prostate cancer?
0:42
How will EIK1003 fit in the treatment landscape of prostate cancer?
Guru Sonpavde • 24 Oct 2026
Assessing the safety and efficacy of EIK1003, a novel selective PARP1 inhibitior
0:39
Assessing the safety and efficacy of EIK1003, a novel selective PARP1 inhibitior
Guru Sonpavde • 24 Oct 2026
EIK1003-001: EIK1003 plus abiraterone in metastatic prostate cancer
1:20
EIK1003-001: EIK1003 plus abiraterone in metastatic prostate cancer
Guru Sonpavde • 24 Oct 2026
KEYNOTE-905/EV-303: perioperative EV and pembrolizumab in MIBC
2:33
KEYNOTE-905/EV-303: perioperative EV and pembrolizumab in MIBC
Guru Sonpavde • 19 Oct 2025

Related Videos

Real-world outcomes highlight unmet needs in R/R germ cell tumors
1:26
Real-world outcomes highlight unmet needs in R/R germ cell tumors
Darren Feldman • 24 Oct 2026
The future of targeting claudin-6 in relapsed germ cell tumors
0:52
The future of targeting claudin-6 in relapsed germ cell tumors
Darren Feldman • 24 Oct 2026
CATALINA-1: ixotatug vedotin, a claudin 6-targeted ADC, in germ cell tumors
2:18
CATALINA-1: ixotatug vedotin, a claudin 6-targeted ADC, in germ cell tumors
Darren Feldman • 24 Oct 2026
How will EIK1003 fit in the treatment landscape of prostate cancer?
0:42
How will EIK1003 fit in the treatment landscape of prostate cancer?
Guru Sonpavde • 24 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals